The Use of Bruton Tyrosine Kinase Inhibitors in Waldenström’s Macroglobulinemia

2Citations
Citations of this article
6Readers
Mendeley users who have this article in their library.

Abstract

The use of Bruton Tyrosine Kinase (BTK) inhibitors in Waldenström’s Macroglobulinemia (WM) is evolving. Ibrutinib, a first-generation BTK inhibitor, is currently approved for use in frontline and relapsed/refractory disease. Second-generation BTK inhibitors are being used and studied to improve clinical outcomes and/or safety profile. Zanubrutinib, one such second-generation inhibitor, was recently approved in treatment-naive and refractory/relapsed patients. Here, we review the use of BTK inhibitors in WM in front-line and refractory or relapsed settings. We also highlight common adverse events, the emergence of BTK inhibitors resistance, and future directions of their use.

Cite

CITATION STYLE

APA

Ababneh, O., Abushukair, H., Qarqash, A., Syaj, S., & Al Hadidi, S. (2022, June 1). The Use of Bruton Tyrosine Kinase Inhibitors in Waldenström’s Macroglobulinemia. Clinical Hematology International. Springer Nature. https://doi.org/10.1007/s44228-022-00007-5

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free